S&P 500   2,997.87 (+1.07%)
DOW   27,036.90 (+0.93%)
QQQ   193.36 (+1.18%)
AAPL   235.89 (+0.01%)
MSFT   141.44 (+1.35%)
GOOGL   1,240.65 (+1.88%)
CGC   19.99 (+5.99%)
NVDA   198.56 (+6.45%)
MU   46.30 (+3.21%)
TSLA   259.27 (+0.90%)
AMD   30.65 (+0.39%)
T   37.87 (+1.07%)
DIS   129.80 (+0.08%)
S&P 500   2,997.87 (+1.07%)
DOW   27,036.90 (+0.93%)
QQQ   193.36 (+1.18%)
AAPL   235.89 (+0.01%)
MSFT   141.44 (+1.35%)
GOOGL   1,240.65 (+1.88%)
CGC   19.99 (+5.99%)
NVDA   198.56 (+6.45%)
MU   46.30 (+3.21%)
TSLA   259.27 (+0.90%)
AMD   30.65 (+0.39%)
T   37.87 (+1.07%)
DIS   129.80 (+0.08%)
Log in

Bio-Rad Laboratories Stock Price, News & Analysis (NYSE:BIO)

$334.00
+2.45 (+0.74 %)
(As of 10/15/2019 12:42 PM ET)
Today's Range
$332.82
Now: $334.00
$336.01
50-Day Range
$320.26
MA: $335.43
$345.24
52-Week Range
$220.05
Now: $334.00
$348.39
Volume45,483 shs
Average Volume224,257 shs
Market Capitalization$9.95 billion
P/E Ratio57.19
Dividend YieldN/A
Beta1.16
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP09057220
Phone510-724-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.29 billion
Cash Flow$5.98 per share
Book Value$134.91 per share

Profitability

Net Income$365.61 million

Miscellaneous

Employees8,260
Market Cap$9.95 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.


Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How will Bio-Rad Laboratories' stock buyback program work?

Bio-Rad Laboratories declared that its Board of Directors has authorized a share repurchase plan on Wednesday, November 29th 2017, which permits the company to repurchase $250,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board believes its stock is undervalued.

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its quarterly earnings data on Thursday, August, 1st. The medical research company reported $1.57 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.39 by $0.18. The medical research company earned $572.60 million during the quarter, compared to the consensus estimate of $564.88 million. Bio-Rad Laboratories had a return on equity of 3.92% and a net margin of 39.32%. The firm's revenue was down .6% on a year-over-year basis. During the same period last year, the firm earned $1.64 earnings per share. View Bio-Rad Laboratories' Earnings History.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Bio-Rad Laboratories.

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.38171336-2.393163905 billion, compared to the consensus revenue estimate of $2.35 billion.

What price target have analysts set for BIO?

3 equities research analysts have issued 12-month price objectives for Bio-Rad Laboratories' stock. Their predictions range from $375.00 to $400.00. On average, they anticipate Bio-Rad Laboratories' share price to reach $385.00 in the next year. This suggests a possible upside of 15.4% from the stock's current price. View Analyst Price Targets for Bio-Rad Laboratories.

What is the consensus analysts' recommendation for Bio-Rad Laboratories?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bio-Rad Laboratories.

Has Bio-Rad Laboratories been receiving favorable news coverage?

News headlines about BIO stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bio-Rad Laboratories earned a news sentiment score of -1.1 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Bio-Rad Laboratories.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest in September. As of September 30th, there was short interest totalling 459,100 shares, an increase of 27.2% from the August 30th total of 360,800 shares. Based on an average trading volume of 208,500 shares, the days-to-cover ratio is currently 2.2 days. Approximately 2.2% of the company's stock are short sold. View Bio-Rad Laboratories' Current Options Chain.

Who are some of Bio-Rad Laboratories' key competitors?

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), First Solar (FSLR), Dynavax Technologies (DVAX), ImmunoGen (IMGN), Celgene (CELG), Exelixis (EXEL) and Array Biopharma (ARRY).

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 69)
  • Ms. Christine A. Tsingos, Exec. Officer (Age 60)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 63)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 57)
  • Ms. Annette Tumolo, Exec. VP & Pres of Life Science Group (Age 64)

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Artemis Investment Management LLP (0.31%), Pacer Advisors Inc. (0.03%), Roubaix Capital LLC (0.03%), State of Alaska Department of Revenue (0.01%), Crossmark Global Holdings Inc. (0.01%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Christine A Tsingos, Giovanni Magni, James R Stark, John Hertia, Michael Crowley and Timothy S Ernst. View Institutional Ownership Trends for Bio-Rad Laboratories.

Which institutional investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, Pacer Advisors Inc. and Crossmark Global Holdings Inc.. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Annette Tumolo, Christine A Tsingos, James R Stark, John Hertia, Michael Crowley and Timothy S Ernst. View Insider Buying and Selling for Bio-Rad Laboratories.

Which institutional investors are buying Bio-Rad Laboratories stock?

BIO stock was bought by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, State of Alaska Department of Revenue, Nelson Van Denburg & Campbell Wealth Management Group LLC, First Hawaiian Bank and Valeo Financial Advisors LLC. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $333.67.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $9.94 billion and generates $2.29 billion in revenue each year. The medical research company earns $365.61 million in net income (profit) each year or $5.84 on an earnings per share basis. Bio-Rad Laboratories employs 8,260 workers across the globe.View Additional Information About Bio-Rad Laboratories.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is http://www.bio-rad.com/.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  315 (Vote Underperform)
Total Votes:  624
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel